查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591796

血友病治疗市场：依产品类型、适应症、分布 - 全球预测 2025-2030

Hemophilia Treatment Market by Product Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates), Disease Indication (Hemophilia A, Hemophilia B, Polyethylene), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血友病治疗市值为143.2亿美元，预计到2024年将达到152.3亿美元，复合年增长率为6.45%，预计到2030年将达到221.8亿美元。

血友病治疗包括多种治疗药物，包括因子替代疗法、基因疗法和非因子疗法，旨在控制以凝血蛋白缺乏为特征的出血性疾病。对血友病晚期治疗的需求源于透过减少出血事件、提高身体独立性和尽量减少关节损伤来提高患者生活品质的需要。这些治疗可用作预防性治疗和按需治疗，其中预防性治疗用于防止严重血友病患者的自发性出血。主要最终使用者包括医院、专科诊所和家庭护理机构，反映了多样化的护理管理需求。该市场受到血友病管理意识的提高、政府积极主动的倡议、药物进步以及血友病遗传患病率增加等因素的支持。随着基因疗法的兴起（有望提供潜在的治疗方法）以及长效重组和非因子疗法的发展，存在着巨大的商机。由于医疗需求未被满足，医疗保健普及率不断提高的新兴市场提供了更大的成长机会。然而，治疗成本上升、严格的法律规范以及开发抑制剂的风险等挑战构成了重大障碍。此外，新兴市场有限的医疗基础设施可能会阻碍市场扩张。生物技术、个人化医疗和具有成本效益的製造方法的创新可以推动业务成长。在这些领域的投资以及技术开发和市场渗透的策略伙伴关係都是可取的。市场的特点是竞争激烈、研究不断、产品发布频繁。公司应该专注于让治疗更安全、更有效、更容易获得。随着市场多元化和快速发展，维持强有力的上市后监测以降低风险并持续调整病患教育对于确保长期成功至关重要。

主要市场统计
基准年[2023] 143.2亿美元
预测年份 [2024] 152.3亿美元
预测年份 [2030] 221.8亿美元
复合年增长率（%） 6.45%

市场动态：快速发展的血友病治疗市场的关键市场洞察

血友病治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 血友病患者数量增加
    • 提高对血友病的诊断和认识
    • 对重组凝血因子 VIII 和血浆凝血因子 IX 的需求不断增加
  • 市场限制因素
    • 与血浆衍生产品相关的严重副作用
  • 市场机会
    • 提高诊断率及预防性治疗
    • 血友病治疗新进展与创新
  • 市场挑战
    • 重组产品高成本且政府法规严格

波特五力：开拓血友病治疗市场的策略工具

波特的五力架构是了解血友病治疗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血友病治疗市场的外在影响

外部宏观环境因素在塑造血友病治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血友病治疗市场的竞争格局

血友病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血友病治疗市场供应商的绩效评估

FPNV定位矩阵是评估血友病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製血友病治疗市场的成功之路

血友病治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 血友病患者增加
      • 提高对血友病的诊断和认识
      • 对重组和血浆衍生的因子 VIII 和因子 IX 的需求增加
    • 抑制因素
      • 与血浆衍生产品相关的严重副作用
    • 机会
      • 提高诊断率并增加预防性治疗的使用
      • 血友病治疗新进展与创新
    • 任务
      • 重组产品的高成本和严格的政府法规
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 血友病治疗市场：依产品类型

  • 抗纤溶药
  • 去氨加压素
  • 血浆衍生凝血因子浓缩物
  • 重组凝血因子浓缩物

第七章 血友病治疗市场：依疾病适应症

  • A型血友病
  • B型血友病
  • 聚乙烯

第八章 血友病治疗市场经销商

  • 电子商务
  • 医院药房
  • 零售药房

第九章美洲血友病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区血友病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的血友病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aptevo Therapeutics
  • Biogen Inc.
  • Biotest AG
  • Bioverativ Inc.
  • CSL Behring
  • F. Hoffmann-La Roche AG
  • Ferring BV
  • Genentech, Inc.
  • Grifols SA
  • Kedrion SPA
  • LAKEMEDEL AB
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4316E4E894CE

The Hemophilia Treatment Market was valued at USD 14.32 billion in 2023, expected to reach USD 15.23 billion in 2024, and is projected to grow at a CAGR of 6.45%, to USD 22.18 billion by 2030.

Hemophilia treatment encompasses a wide array of therapeutics, including factor replacement therapies, gene therapy, and non-factor therapies aimed at managing bleeding disorders characterized by a deficiency in blood-clotting proteins. The necessity for advanced hemophilia therapies stems from the need to elevate patients' quality of life by reducing bleeding episodes, improving physical independence, and minimizing joint damage. These treatments find applications in both prophylactic and on-demand settings, with prophylaxis being favored to prevent spontaneous bleeding in severe hemophilia cases. Key end-users include hospitals, specialty clinics, and home-care settings, reflecting the diverse treatment administration requirements. The market is propelled by factors such as heightened awareness about hemophilia management, favorable government initiatives, advancements in pharmaceutical products, and the growing genetic prevalence of the disorder. Prominent opportunities lie in the rise of gene therapy, which promises a potential cure and the development of long-acting recombinant and non-factor therapies. Emerging markets with increasing healthcare access offer substantial growth opportunities due to unmet medical needs. However, challenges like the high cost of therapies, stringent regulatory frameworks, and the risk of inhibitor development pose significant hindrances. Additionally, limited healthcare infrastructure in developing regions can impede market expansion. Innovation in bioengineering, personalized medicine, and cost-efficient manufacturing methods can fuel business growth. Investment in these areas, along with strategic partnerships for technology development and market penetration, is advisable. The hemophilia treatment market is characterized by intense competition with ongoing research and frequent product launches. Firms should focus on enhancing therapy safety and efficacy, and increasing accessibility. Maintaining robust post-market surveillance to mitigate risks and continuously tailoring patient education will be critical in ensuring long-term success as the market diversifies and evolves rapidly.

KEY MARKET STATISTICS
Base Year [2023] USD 14.32 billion
Estimated Year [2024] USD 15.23 billion
Forecast Year [2030] USD 22.18 billion
CAGR (%) 6.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemophilia Treatment Market

The Hemophilia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of cases of hemophilia
    • Rising diagnostic and awareness related to Hemophilia
    • Increasing demand for recombinant and plasma-derived factor VIII and factor IX
  • Market Restraints
    • Serious adverse effects associated with plasma-derived products
  • Market Opportunities
    • Increased diagnosis rate and rise in the use of prophylactic treatment
    • Emerging advances and innovations in hemophilia treatment
  • Market Challenges
    • High cost of recombinant products and stringent government regulations

Porter's Five Forces: A Strategic Tool for Navigating the Hemophilia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemophilia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemophilia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemophilia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemophilia Treatment Market

A detailed market share analysis in the Hemophilia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemophilia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemophilia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemophilia Treatment Market

A strategic analysis of the Hemophilia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemophilia Treatment Market, highlighting leading vendors and their innovative profiles. These include Aptevo Therapeutics, Biogen Inc., Biotest AG, Bioverativ Inc., CSL Behring, F. Hoffmann-La Roche AG, Ferring B.V., Genentech, Inc., Grifols SA, Kedrion S.P.A, LAKEMEDEL AB, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hemophilia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates.
  • Based on Disease Indication, market is studied across Hemophilia A, Hemophilia B, and Polyethylene.
  • Based on Distribution, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of cases of hemophilia
      • 5.1.1.2. Rising diagnostic and awareness related to Hemophilia
      • 5.1.1.3. Increasing demand for recombinant and plasma-derived factor VIII and factor IX
    • 5.1.2. Restraints
      • 5.1.2.1. Serious adverse effects associated with plasma-derived products
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased diagnosis rate and rise in the use of prophylactic treatment
      • 5.1.3.2. Emerging advances and innovations in hemophilia treatment
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of recombinant products and stringent government regulations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemophilia Treatment Market, by Product Type

  • 6.1. Introduction
  • 6.2. Antifibrinolytic Agents
  • 6.3. Desmopressin
  • 6.4. Plasma Derived Coagulation Factor Concentrates
  • 6.5. Recombinant Coagulation Factor Concentrates

7. Hemophilia Treatment Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A
  • 7.3. Hemophilia B
  • 7.4. Polyethylene

8. Hemophilia Treatment Market, by Distribution

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Hemophilia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemophilia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemophilia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aptevo Therapeutics
  • 2. Biogen Inc.
  • 3. Biotest AG
  • 4. Bioverativ Inc.
  • 5. CSL Behring
  • 6. F. Hoffmann-La Roche AG
  • 7. Ferring B.V.
  • 8. Genentech, Inc.
  • 9. Grifols SA
  • 10. Kedrion S.P.A
  • 11. LAKEMEDEL AB
  • 12. Novo Nordisk A/S
  • 13. Octapharma AG
  • 14. Pfizer Inc.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. HEMOPHILIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOPHILIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMOPHILIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOPHILIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DESMOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY PLASMA DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMOPHILIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEMOPHILIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEMOPHILIA TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. HEMOPHILIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. HEMOPHILIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023